Psychopharmacology
Medication remains a cornerstone of treatment for most mental illnesses. For this reason, MAPrc is committed to investigating new and improved medications for serious mental illnesses such as schizophrenia, bipolar affective disorder, major depression, anxiety and other disorders.
In keeping with our research philosophy of equality, respect and understanding, the clinical trials that we undertake are limited in number and aim to provide better symptom resolution. We do not undertake studies that contain placebo-only groups and we require that the active medications being trialled are ones that have been shown in preliminary trials to be superior to currently available medications. During trials, we take care to monitor the participants’ subjective assessments of their experience, the effects of the trial medications and other general responses. We also invite carers to give their views and opinions about the treatments being studied.
In recent years, a number of new and improved treatments have become available, and advances in biotechnology are paving the way for new techniques for drug discovery. We believe that the future holds substantial hope for new and better treatment options for people living with devastating mental illnesses.
Psychopharmacology research team
Team Leader
Prof. Jayashri Kulkarni
Coordinator
Dr. Siva Ilancheran
Medical Officer
Dr. Iffat Imtiaz
Researchers
Ms. Erica Hannagan
Mr. Scott Santinon
Ms. Niharika Anand
Ms. Penny Weeks
Ms. Natalia Contreras
